Neurology

Myrtelle’s therapy targets oligodendrocytes to deliver a functional copy of the ASPA gene.

The global head of research and development at Atara Biotherapeutics discussed the link between EBV and MS.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The FDA has approved LEXEO Therapeutics’ investigational new drug application.

Interim safety data from the FORTIS study were presented at WORLDSympsoium.

The chief scientific officer of FibroBiologics discussed the advantages of fibroblast cell therapy over stem cell therapy.

Positive results from a phase 1/2 study of AXO-AAV-GM1 were presented at WORLDSymposium.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in gene and cell therapies.

SwanBio previously presented positive preclinical data at the ESGCT 2021 meeting.

The positive news is countered by a report of a patient death in Taysha’s gene therapy program for GM2 gangliosidosis.

Review top news and interview highlights from the week ending January 28, 2022.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in gene and cell therapies.

Investigators from IRCCS San Raffaele analyzed results from a phase 1/2 study on atidarsagene autotemcel.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in gene and cell therapies.

Eli-cel remains on clinical hold in cerebral adrenoleukodystrophy after a report of persistent anemia.

Review top news and interview highlights from the week ending January 14, 2022.

Many cell and gene therapy companies are initiating new programs and collaborations with the start of the new year.

The placebo crossover cohort experienced statistically significant improvements in NSAA score over external control.

Review top news and interview highlights from the week ending January 7, 2022.

The DSMB has recommended that enrollment expand and doses be escalated from 3.3 to 5 mg in 1 cohort of the KIK-AS study.

Data from a phase 1/2 trial of AMT-130 supports continued enrollment for a higher-dose cohort of 6 x 1013 vg.

The director of the Buffalo Neuroimaging Analysis Center and professor of Universtiy of Buffalo discussed avenues of research into reversing neurodegeneration in MS.

Review some of our most-viewed coverage of advancements in cell therapies, including the latest study results and insights from experts in the field.

Review top news and interview highlights from the week ending December 24, 2021.